Email bulletin archive Archive December 2017 Hepatitis B: experimental treatments Treatment for acute HCV infection Hepatitis C services in the United Kingdom: lessons for improving diagnosis and treatment of people who inject drugs Drug policy in Portugal Is this your copy of the infohep news bulletin? November 2017 World Hepatitis Summit news Low rates of diagnosis High cost of treatment and measures to reduce drug costs New financing mechanisms needed Nivolumab improves outcomes in liver cancer Cost-effectiveness of HCV treatment in Japan New hepatitis B vaccine Is this your copy of the infohep news bulletin? October 2017 News from The Liver Meeting 2017 Quality of life improves after hepatitis C cure Hepatitis C testing and reduced opioid use NAFLD and NASH Liver cancer and viral hepatitis Hepatitis C elimination in people with HIV Challenge to Gilead’s US patent on sofosbuvir Genotype 3 treatment Is this your copy of the infohep news bulletin? September 2017 Progress towards elimination of hepatitis C Global Burden of Disease study shows viral hepatitis causes more deaths than HIV or TB Debate: Not all drug preparation equipment may contain infectious HCV Women who inject drugs at greater risk of HCV Nivolumab (Opdivo) approved for hepatocellular carcinoma treatment in the United States Janssen halts hepatitis C drug research Next month: news coverage of The Liver Meeting 2017 Is this your copy of the infohep news bulletin? August 2017 World Hepatitis Day: steps towards elimination Drug prices: time to shift from talking about high prices to low production costs Hepatitis C: DAA treatment and mortality Vosevi approved in the European Union and United States Maviret approved in the European Union and United States Epclusa use expanded to people with HIV co-infection in the United States Harvoni licence extended to adolescents aged 12-18 years in European Union Hepatitis C treatment in Africa Non-alcoholic fatty liver disease in people living with HIV Is this your copy of the infohep news bulletin? June 2017 Cochrane review of hepatitis C treatment strongly criticised New pangenotypic drug combinations Recent infection with hepatitis C and testing for hepatitis C Sofosbuvir treatment for adolescents and children US monitoring and surveillance recommendations Coming soon: IAS 2017 Is this your copy of the infohep news bulletin? May 2017 New hepatitis C infections in the United States HCV reinfection among people who inject drugs Gilead warning on generics – weeks after more evidence on effectiveness Albumin treatment in decompensated cirrhosis New drugs for hepatitis B treatment Is this your copy of the infohep news bulletin? April 2017 News from the 2017 International Liver Congress WHO Global Hepatitis Report 2017 New hepatitis B clinical guidelines from EASL HCV reimbursement criteria in Europe Direct-acting antivirals and liver cancer risk Hepatitis C treatment for children AbbVie combination HCV treatment reduces cardiovascular risk Parkinson’s disease and hepatitis Statins reduce the risk of decompensation Antibiotic prophylaxis reduces mortality in decompensated cirrhosis Coming soon: HR17 Is this your copy of the infohep news bulletin? March 2017 Early treatment for hepatitis C Access to hepatitis C treatment in South East Asia Cancers Liver cancer and treatment for viral hepatitis Direct-acting antiviral treatment achieves high cure rates in the most advanced liver disease patients with HIV co-infection Glecaprevir/pibrentasvir combination does not interact with HIV medications Hepatitis A outbreak in Europe Hepatitis C community summit, 18 & 19 April, Amsterdam Is this your copy of the infohep news bulletin? February 2017 HCV treatment as prevention Progress towards HCV elimination Guidelines on HCV and HBV testing Effects of hepatitis C cure on extrahepatic disease in people with HIV/HCV co-infection Lonafarnib for hepatitis delta Is this your copy of the infohep news bulletin? January 2017 Hep-CORE Direct-acting antiviral treatment and kidney disease Liver transplant demand Liver cancer treatment Vemlidy for hepatitis B approved in European Union Counterfeit Harvoni found in Japan Is this your copy of the infohep news bulletin? 2022202120202019201820172016201520142013 Other pages in this section Latest news All the news Conference news Email bulletin archive